Merus NV

Canaccord Genuity analyst John Newman maintains a Buy rating on Merus (MRUS) stock, citing the strategic partnership with Partner Therapeutics to commercialize Zenocutuzumab in the US. This collaboration allows Merus to focus on petosemtamab, with Zenocutuzumab's potential US approval and manufacturing issues resolution supporting a positive outlook. Newman sets a $67 price target.

Merus N.V., a clinical-stage biotech, focuses on bispecific antibody therapies for cancer. Its lead candidate, petosemtamab, shows promising results in HNSCC trials, potentially outperforming cetuximab. The company's innovative platform positions it as a disruptor in oncology, though early-stage programs and high R&D costs pose risks. Analysts project revenue growth and potential market expansion beyond current indications.

Novocure's electrical field-emitting device in Phase 3 trial showed extended survival in pancreatic cancer patients when used with chemo; Merus licensed U.S. rights of its cancer drug zenocutuzumab to Partner Therapeutics; FDA to decide on Cytokinetics' heart drug aficamten approval by Sept. 26, 2025; FDA investigates blood cancer cases post-Bluebird bio's Skysona treatment; Fate Therapeutics' CEO Scott Wolchko to retire, with Bob Valamehr taking over in 2025.

Les données intermédiaires de l'étude de phase II sur le pétosemtamab montrent une activité cliniquement significative dans le traitement de 2e ligne et au-delà du CETC. Une téléconférence est prévue pour discuter des résultats complets.

Merus announces updated petosemtamab data showing 40.4% response rate in 2L+ HNSCC, with 7.2 months median duration of response and 12.5 months median overall survival. The data will be presented at ESMO Asia Congress 2024, followed by a conference call on Dec. 7.

Merus announced updated clinical data for petosemtamab in r/m HNSCC, showing a 40.4% response rate among 47 evaluable patients at 1500mg Q2W, with 7.2 months median duration of response and 12.5 months median overall survival. A dose comparison study indicated stronger efficacy at 1500mg (5 responses, including 1 complete response in 12 evaluable patients) compared to 1100mg (1 confirmed response in 10 patients), with both doses well-tolerated and no grade 5 adverse events reported.

ATB Therapeutics BV raised €54m in Series A financing to develop oncology/immunology drugs via its ATBioFarm platform, producing ADC-like fusion proteins in tobacco plants. The financing was co-led by EQT LifeSciences and MRL Ventures Fund, with additional investors. ATB plans to expand its platform and appoint Mark Throsby as Executive Chairman.

FDA extends review of Merus' bispecific antibody zenocutuzumab, targeting non-small cell lung cancer and pancreatic ductal adenocarcinoma with specific genetic mutations, due to additional CMC information submission. New action date set for Feb. 4, 2025. No clinical data issues identified. Zenocutuzumab disrupts HER2 and HER3 binding to inhibit cancer cell proliferation. Merus also developing petosemtamab for head and neck squamous cell carcinoma and metastatic colorectal cancer.

The FDA extended the PDUFA target action date for zenocutuzumab's BLA to February 4, 2025, for NRG1+ NSCLC and pancreatic cancer. Priority review was granted in May 2024, with additional time needed for chemistry, manufacturing, and controls assessment.

The article discusses the importance of SSR (Server-Side Rendering) in modern web development, emphasizing its role in enhancing performance and user experience.